CVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related Indication: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 14, 2025
October 15, 2025
f3901b25-31a8-481c-abe2-0be5e9380650
Related Documents
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry
Guidance DocumentJuly 8, 2019Center for Drug Evaluation and Research
Temporary Policies for Compounding Certain Parenteral Drug Products: Guidance for Industry
Guidance DocumentOctober 11, 2024Center for Drug Evaluation and Research
CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs
Guidance DocumentApril 4, 2016Center for Veterinary Medicine
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.